CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 104 enrolled
Drug / intervention
Collagenase Clostridium Histolyticumdrug
Likely dose
Collagenase Clostridium Histolyticum 0.58 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01588353
NCT01588353Phase 3Completed
CompareCT.gov

Phase III Study of AK160 in Patients With Dupuytren's Contracture

Asahi Kasei Therapeutics Corporation·interventional·Posted Apr 30, 2012·Updated Mar 21, 2017

In Brief

A Phase 3 clinical trial evaluating Collagenase Clostridium Histolyticum for Dupuytren's Contracture. Completed, enrolled 104 participants across 20 sites.

Detailed Summary

To investigate the efficacy and safety of AK160 in patients with Dupuytren's Contracture. To determine plasma concentration after the first injection of AK160 in patients with Dupuytren's Contracture.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDupuytren's Contracture
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 30, 2012
Enrollment StartMay 1, 2012
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 14.2 years ago

Interventions

Collagenase Clostridium Histolyticumdrug

AK160 (Collagenase Clostridium Histolyticum) 0.58 mg